GO:0032717 negative regulation of interleukin-8 production: Signaling Control, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0032717 describes any biological process that stops, prevents, or reduces the frequency, rate, or extent of interleukin-8 (IL-8/CXCL8) production.
• IL-8 is a pro-inflammatory CXC chemokine; its negative regulation is critical for limiting neutrophil recruitment and tissue damage.
• Key negative regulators include interferon-gamma (IFNG), protein tyrosine phosphatase 1B (PTPN1), and the lipid-metabolism enzyme ECI2.
• Dysregulation of IL-8 negative regulation is implicated in cancer progression, metastasis, and chronic inflammatory diseases.
• Experimental approaches to study GO:0032717 include CRISPR knockout of negative regulators, overexpression of suppressors, and cytokine profiling.
• Understanding this process informs therapeutic strategies to modulate IL-8 in melanoma, hepatocellular carcinoma, and airway inflammation.
Description
Interleukin-8 (IL-8), also known as CXCL8, is a pro-inflammatory chemokine that recruits neutrophils and promotes angiogenesis, tumor growth, and metastasis. The Gene Ontology term GO:0032717, negative regulation of interleukin-8 production, encompasses any process that stops, prevents, or reduces the frequency, rate, or extent of IL-8 production. This regulation is essential for resolving inflammation and preventing excessive tissue damage. Researchers study GO:0032717 to identify molecular brakes on IL-8 synthesis, which are frequently dysregulated in cancer and chronic inflammatory diseases. For example, interferon-gamma (IFNG) inhibits IL-8 production by human polymorphonuclear leucocytes, highlighting a physiological negative feedback mechanism. Similarly, protein tyrosine phosphatase 1B (PTPN1) regulates platelet-activating factor-induced IL-8 expression, demonstrating the involvement of phosphatase signaling. The lipid-metabolism enzyme ECI2 reduces neutrophil extracellular trap formation and suppresses colorectal cancer, partly through negative regulation of IL-8 production. These findings underscore the importance of GO:0032717 in immune homeostasis and disease pathogenesis.
negative regulation of interleukin-8 production At A Glance
| GO ID | GO:0032717 |
|---|---|
| GO term | negative regulation of interleukin-8 production |
| Ontology | biological_process |
| Synonym | down regulation of interleukin-8 production; down-regulation of interleukin-8 production; downregulation of interleukin-8 production; inhibition of interleukin-8 production; negative regulation of IL-8 production; negative regulation of interleukin-8 biosynthetic process; negative regulation of interleukin-8 secretion |
| Major function | Suppression of IL-8 (CXCL8) production, limiting neutrophil recruitment and inflammation |
| Related processes | Regulation of inflammatory response, chemokine production, neutrophil chemotaxis |
| Key regulators | IFNG, PTPN1, ECI2, and other signaling molecules |
| Disease relevance | Cancer, chronic inflammation, airway diseases, autoimmune disorders |
What Is GO:0032717?
GO:0032717 is a biological process defined as any process that stops, prevents, or reduces the frequency, rate, or extent of interleukin-8 production. This includes inhibition of IL-8 biosynthesis, secretion, or overall production. The term is synonymous with down regulation, down-regulation, downregulation, inhibition of interleukin-8 production, negative regulation of IL-8 production, negative regulation of interleukin-8 biosynthetic process, and negative regulation of interleukin-8 secretion.
Why Is negative regulation of interleukin-8 production Important in Cell Biology?
Negative regulation of interleukin-8 production is critical for controlling inflammation and preventing tissue damage. IL-8 is a potent chemoattractant for neutrophils and promotes angiogenesis and tumor progression. Without proper negative regulation, excessive IL-8 leads to chronic inflammation, autoimmune diseases, and cancer metastasis. Understanding GO:0032717 provides insights into molecular mechanisms that restrain IL-8, offering therapeutic targets for inflammatory diseases and cancer.
• Limits neutrophil recruitment and prevents excessive inflammation.
• Reduces angiogenesis and tumor growth in melanoma and other cancers.
• Suppresses metastasis in hepatocellular carcinoma by inhibiting IL-8 production.
• Modulates airway epithelial signaling and lung inflammation.
• Involves phosphatases such as PTPN1 that dephosphorylate signaling intermediates.
• Interferon-gamma acts as a negative regulator of IL-8 in polymorphonuclear leucocytes.
• ECI2 reduces neutrophil extracellular traps and colorectal cancer progression.
• Dysregulation contributes to chronic inflammatory diseases and autoimmune disorders.
• Provides targets for anti-inflammatory and anti-cancer therapies.
• Essential for understanding chemokine network homeostasis.
What Happens During negative regulation of interleukin-8 production?
Initiation of negative regulatory signals
In simple terms: A signal tells the cell to stop making IL-8.
Negative regulation of IL-8 production begins when extracellular or intracellular signals activate inhibitory pathways. For example, interferon-gamma (IFNG) binds to its receptor and triggers signaling that inhibits IL-8 production in human polymorphonuclear leucocytes. Similarly, platelet-activating factor (PAF) can induce IL-8, but protein tyrosine phosphatase 1B (PTPN1) acts as a negative regulator of this process. These signals converge on transcriptional and post-transcriptional mechanisms to reduce IL-8 synthesis.
Transcriptional suppression of IL-8 gene expression
In simple terms: The cell reduces the reading of the IL-8 gene.
At the transcriptional level, negative regulators can inhibit the activity of transcription factors such as NF-kB and AP-1 that drive IL-8 gene expression. For instance, IFNG-mediated inhibition of IL-8 production involves interference with transcriptional activation. PTPN1 may dephosphorylate signaling intermediates, leading to reduced NF-kB activation and subsequent IL-8 transcription. The exact transcription factors affected depend on the cell type and stimulus.
Post-transcriptional and secretory inhibition
In simple terms: The cell stops making or releasing the IL-8 protein.
Negative regulation can also occur post-transcriptionally by destabilizing IL-8 mRNA or inhibiting its translation. Additionally, secretion of IL-8 can be blocked. For example, ECI2 reduces neutrophil extracellular trap formation and suppresses colorectal cancer, partly by negatively regulating IL-8 production. The precise molecular mechanisms may involve mRNA-binding proteins or microRNAs, though specific details require further study.
Integration with cellular signaling networks
In simple terms: The stop signal is connected to other cell decisions.
Negative regulation of IL-8 production is integrated with broader signaling networks. For example, ligand-independent CXCR2 dimerization can influence IL-8 signaling and production. Gi2 proteins positively regulate T cell activation and IL-8, suggesting that negative regulators may counteract such positive signals. The balance between positive and negative regulation determines net IL-8 output.
Key Genes Involved in GO:0032717 negative regulation of interleukin-8 production
The following genes and proteins are experimentally implicated in the negative regulation of interleukin-8 production, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| IFNG | Inhibits IL-8 production in polymorphonuclear leucocytes | Studied for anti-inflammatory effects |
| PTPN1 | Protein tyrosine phosphatase 1B; negatively regulates PAF-induced IL-8 expression | Target for modulating inflammation |
| ECI2 | Lipid-metabolism enzyme; reduces NET formation and suppresses colorectal cancer via IL-8 negative regulation | Potential tumor suppressor |
| CXCR2 | Receptor for IL-8; ligand-independent dimerization affects signaling | Modulates IL-8 feedback |
| GNAI2 | Gi2 protein; positively regulates T cell activation and IL-8 | Indirectly related to negative regulation |
| IL8 | The chemokine itself; its production is negatively regulated | Central to GO:0032717 |
| NFKB1 | Transcription factor driving IL-8 expression; inhibited by negative regulators | Common target of suppression |
| RELA | NF-kB subunit; involved in IL-8 transcription | Potential indirect target |
| MAPK1 | Signaling kinase; may be dephosphorylated by PTPN1 | Upstream of IL-8 |
| MAPK3 | Signaling kinase; involved in IL-8 induction | Upstream of IL-8 |
| SRC | Tyrosine kinase; may be regulated by PTPN1 | Signaling intermediate |
| STAT1 | Mediates IFNG signaling; contributes to IL-8 inhibition | Key negative regulator |
| JAK1 | Janus kinase; upstream of STAT1 in IFNG signaling | Mediates IFNG effects |
| JAK2 | Janus kinase; involved in cytokine signaling | Potential mediator |
| PIK3CA | PI3K subunit; may influence IL-8 production | Signaling context |
| AKT1 | Kinase; downstream of PI3K; may modulate IL-8 | Signaling context |
| MAPK14 | p38 MAPK; involved in IL-8 regulation | Stress signaling |
How Is negative regulation of interleukin-8 production Regulated?
Negative regulation of IL-8 production is itself controlled by various signaling pathways. For example, interferon-gamma (IFNG) activates JAK-STAT signaling to inhibit IL-8 production. Protein tyrosine phosphatase 1B (PTPN1) dephosphorylates targets to dampen IL-8 expression induced by platelet-activating factor. The lipid-metabolism enzyme ECI2 negatively regulates IL-8 production, linking metabolic pathways to inflammatory control. Additionally, ligand-independent CXCR2 dimerization may influence IL-8 feedback. These regulatory layers ensure tight control of IL-8 levels.
negative regulation of interleukin-8 production and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| ECI2 | Colorectal cancer suppression via reduced NETs and IL-8 | ECI2 knockout or overexpression in colorectal cancer cell lines |
| PTPN1 | Inflammation regulation; PAF-induced IL-8 | PTPN1 knockout or overexpression in immune cells |
| IL8 | Melanoma growth and metastasis | IL-8 knockdown or overexpression in melanoma models |
| IFNG | Inhibition of IL-8 in leucocytes; anti-inflammatory | IFNG treatment or knockout in neutrophil models |
| IL1A | Hepatocellular carcinoma stemness and metastasis | IL1A knockout or overexpression in HCC models |
Cancer progression and metastasis
IL-8 promotes tumor growth, angiogenesis, and metastasis in melanoma and other cancers. Negative regulation of IL-8 production is therefore tumor-suppressive. For instance, ECI2 reduces neutrophil extracellular trap formation and suppresses colorectal cancer, partly by negatively regulating IL-8. In hepatocellular carcinoma, intracellular IL1α in peritumoral monocytes induces IL-8 production, and inhibiting this pathway reduces stemness and metastasis. Thus, restoring negative regulation of IL-8 is a potential therapeutic strategy.
Chronic inflammatory and airway diseases
Excessive IL-8 drives neutrophil infiltration and tissue damage in chronic inflammatory diseases. Interferon-gamma negatively regulates IL-8 production in polymorphonuclear leucocytes, highlighting a mechanism that may be impaired in disease. In airway epithelium, signaling cascades regulate IL-8, and their dysregulation contributes to lung inflammation. Enhancing negative regulation could mitigate inflammatory damage.
Autoimmune and immune disorders
IL-8 is involved in T cell activation and immune cell recruitment. Negative regulation of IL-8 production helps prevent excessive immune responses. PTPN1 regulates PAF-induced IL-8 expression, and its dysfunction may contribute to autoimmune conditions. Understanding these pathways can inform treatments for autoimmune diseases.
From negative regulation of interleukin-8 production-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does ECI2 negatively regulate IL-8 production? | ECI2 knockout and overexpression in colorectal cancer cells |
| How does PTPN1 regulate PAF-induced IL-8? | PTPN1 knockout or point mutant in immune cells |
| Does IFNG inhibit IL-8 in neutrophils? | IFNG receptor knockout or STAT1 knockout |
| What is the role of CXCR2 dimerization in IL-8 feedback? | CXCR2 knock-in of dimerization mutants |
| Does IL1α drive IL-8 in HCC? | IL1A knockout or overexpression in hepatocytes |
| How does airway epithelial signaling regulate IL-8? | Airway epithelial cell lines with pathway perturbations |
How to Study the negative regulation of interleukin-8 production Process
| Method | What It Measures | Typical Application |
|---|---|---|
| ELISA | IL-8 protein concentration in supernatants | Quantify negative regulation |
| qPCR | IL8 mRNA levels | Assess transcriptional suppression |
| RNA-seq | Global transcriptome changes | Identify pathways co-regulated with IL-8 |
| CRISPR knockout | Gene function loss | Discover negative regulators |
| Overexpression | Gain-of-function | Validate suppressors |
| Western blot | Protein expression and phosphorylation | Check signaling intermediates |
| Flow cytometry | Intracellular IL-8 or surface markers | Single-cell analysis |
| Multiplex cytokine assay | Multiple cytokines including IL-8 | Profile inflammatory networks |
CRISPR knockout screens
Genome-wide CRISPR knockout screens can identify genes whose loss increases IL-8 production, revealing negative regulators. For example, knocking out ECI2 or PTPN1 may elevate IL-8, confirming their roles.
Overexpression and rescue experiments
Overexpressing candidate negative regulators such as IFNG or ECI2 can suppress IL-8 production, validating their function. Rescue experiments with point mutants can dissect specific domains.
Cytokine profiling and ELISA
Measuring IL-8 protein levels in supernatants by ELISA or multiplex cytokine arrays quantifies the extent of negative regulation under different conditions.
RNA-seq and qPCR
Transcriptomic analysis of IL-8 mRNA levels reveals transcriptional suppression. qPCR can confirm changes in IL8 gene expression upon perturbation of negative regulators.
How CRISPR Can Be Used to Study GO:0032717 negative regulation of interleukin-8 production
Knockout
CRISPR knockout of candidate negative regulators such as ECI2 or PTPN1 can test whether their loss increases IL-8 production. This approach is used to identify and validate genes involved in GO:0032717.
Point Mutation
Introducing point mutations in catalytic domains of phosphatases like PTPN1 can dissect their role in IL-8 negative regulation. For example, a catalytically dead PTPN1 mutant can reveal whether phosphatase activity is required.
Knock-in
Knock-in of tagged or reporter alleles (e.g., IL8 promoter-driven luciferase) allows real-time monitoring of IL-8 transcription in response to negative regulators. This can be combined with CRISPR to study specific mutations.
Overexpression
CRISPR activation (CRISPRa) or lentiviral overexpression of genes like IFNG or ECI2 can suppress IL-8 production, providing gain-of-function evidence for negative regulation.
How EDITGENE Supports negative regulation of interleukin-8 production Research
Researchers studying negative regulation of interleukin-8 production-related genes often need to determine whether a candidate gene is causally involved in suppressing IL-8. EDITGENE provides comprehensive CRISPR services to accelerate this discovery.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of interleukin-8 production research.
Frequently Asked Questions About negative regulation of interleukin-8 production
What is GO:0032717?
GO:0032717 is the Gene Ontology term for negative regulation of interleukin-8 production, describing any process that stops, prevents, or reduces the frequency, rate, or extent of IL-8 production.
What genes are involved in negative regulation of interleukin-8 production?
Key genes include IFNG, PTPN1, and ECI2, which have been shown to inhibit IL-8 production in various cell types.
How is interleukin-8 production negatively regulated?
Negative regulation occurs through signaling pathways that inhibit transcription, mRNA stability, or secretion of IL-8, often involving phosphatases and cytokines like interferon-gamma.
Why is negative regulation of IL-8 important in cancer?
Excessive IL-8 promotes tumor growth and metastasis; negative regulation suppresses these effects, as seen with ECI2 in colorectal cancer and IL1α in hepatocellular carcinoma.
What diseases are associated with dysregulated IL-8 negative regulation?
Dysregulation is linked to chronic inflammatory diseases, airway inflammation, melanoma, and hepatocellular carcinoma.
How can I study negative regulation of IL-8 production?
Use CRISPR knockout or overexpression of candidate genes, measure IL-8 by ELISA or qPCR, and perform RNA-seq to identify pathways.
What is the role of PTPN1 in IL-8 regulation?
PTPN1 negatively regulates platelet-activating factor-induced IL-8 expression, likely by dephosphorylating signaling intermediates.
Does interferon-gamma inhibit IL-8 production?
Yes, interferon-gamma inhibits IL-8 production by human polymorphonuclear leucocytes, demonstrating a negative regulatory role.
What is the connection between ECI2 and IL-8?
ECI2 reduces neutrophil extracellular trap formation and suppresses colorectal cancer, partly through negative regulation of IL-8 production.
How does CXCR2 dimerization affect IL-8?
Ligand-independent CXCR2 dimerization can influence IL-8 signaling and feedback, though its direct role in negative regulation requires further study.
Conclusion
GO:0032717, negative regulation of interleukin-8 production, is a critical biological process that restrains inflammation and cancer progression. Key regulators such as IFNG, PTPN1, and ECI2 provide molecular brakes on IL-8 synthesis. Dysregulation of this process contributes to melanoma, hepatocellular carcinoma, and chronic inflammatory diseases. Continued research using CRISPR models and cytokine profiling will uncover new therapeutic opportunities.
References
- 1. Chen L et al.. 2024. The lipid-metabolism enzyme ECI2 reduces neutrophil extracellular traps formation for colorectal cancer suppression.. Nat Commun 15(1):7184 PMID: 39169021
- 2. Hamel-Côté G et al.. 2019. Regulation of platelet-activating factor-induced interleukin-8 expression by protein tyrosine phosphatase 1B.. Cell Commun Signal 17(1):21 PMID: 30832675
- 3. Bar-Eli M. 1999. Role of interleukin-8 in tumor growth and metastasis of human melanoma.. Pathobiology 67(1):12-8 PMID: 9873223
- 4. Nakanaga T et al.. 2007. Regulation of interleukin-8 via an airway epithelial signaling cascade.. Am J Physiol Lung Cell Mol Physiol 292(5):L1289-96 PMID: 17220369
- 5. Ruan YH et al.. 2025. Intracellular IL1α in Peritumoral Monocytes Induces IL8 Production and Inhibits Mitophagy to Promote Stemness and Metastasis of Hepatocellular Carcinoma.. Cancer Res 85(21):4164-4181 PMID: 40857615
- 6. Cassatella MA et al.. 1993. Interferon-gamma inhibits interleukin-8 production by human polymorphonuclear leucocytes.. Immunology 78(2):177-84 PMID: 8473010
- 7. Trettel F et al.. 2003. Ligand-independent CXCR2 dimerization.. J Biol Chem 278(42):40980-8 PMID: 12888558
- 8. Lippert E et al.. 2000. Positive regulation of human T cell activation by Gi2 proteins and interleukin-8.. J Leukoc Biol 67(5):742-8 PMID: 10811016
